Fig. 3.

MTC-100038 treatment results in significant efficacy in orthotopic models of HCC and is better than the current standard of care sorafenib. Hep3B-Luc tumor cells were implanted into the left lobe of female BalbC/Nude mice. Mice (n = 10/group) received intravenous injection of either DM1, MTC-100038, or vehicle control for 2 dosing cycles of 5 consecutive days (QD5), separated by 5 days. The sorafenib treatment group received oral administration of 60 mg/kg daily for 21 days. Following administration of luciferin, tumor volumes were visualized by measurement in a IVIS Lumina II imaging system: a tumor growth curves; b images of mice with tumors in situ showing significant differences in luminescence (tumor size) between treatment groups. MTC-100038 is an effect treatment agent. Error bars represent ± SEM. Reprinted with permission from Hale et al. (2019), Bioconjugate Chemistry. Copyright 2019, American Chemical Society (Hale et al. 2019)